Regulus Therapeutics (RGLS) Rating Increased to Buy at Zacks Investment Research

Regulus Therapeutics (NASDAQ:RGLS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Thursday. The firm currently has a $1.25 target price on the biopharmaceutical company’s stock. Zacks Investment Research‘s target price would indicate a potential upside of 0.81% from the stock’s current price.

According to Zacks, “Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company’s products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California. “

Several other equities analysts also recently issued reports on the company. Needham & Company LLC reiterated a “hold” rating on shares of Regulus Therapeutics in a research report on Tuesday, November 14th. Wedbush restated an “outperform” rating and issued a $4.00 target price on shares of Regulus Therapeutics in a research report on Monday, December 11th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and four have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $2.46.

Regulus Therapeutics (NASDAQ RGLS) opened at $1.24 on Thursday. The company has a current ratio of 6.77, a quick ratio of 6.77 and a debt-to-equity ratio of 0.41. The stock has a market capitalization of $128.90, a P/E ratio of -0.93 and a beta of 1.55. Regulus Therapeutics has a 52-week low of $0.79 and a 52-week high of $2.60.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in RGLS. Quantitative Investment Management LLC acquired a new stake in Regulus Therapeutics in the second quarter worth approximately $103,000. GSA Capital Partners LLP acquired a new stake in Regulus Therapeutics in the second quarter worth approximately $139,000. FMR LLC lifted its position in Regulus Therapeutics by 0.5% in the second quarter. FMR LLC now owns 7,977,349 shares of the biopharmaceutical company’s stock worth $7,862,000 after purchasing an additional 37,489 shares during the period. Goldman Sachs Group Inc. lifted its position in Regulus Therapeutics by 189.1% in the second quarter. Goldman Sachs Group Inc. now owns 368,285 shares of the biopharmaceutical company’s stock worth $363,000 after purchasing an additional 240,890 shares during the period. Finally, Royal Bank of Canada lifted its position in Regulus Therapeutics by 12.1% in the second quarter. Royal Bank of Canada now owns 184,040 shares of the biopharmaceutical company’s stock worth $182,000 after purchasing an additional 19,934 shares during the period. Hedge funds and other institutional investors own 59.39% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Regulus Therapeutics (RGLS) Rating Increased to Buy at Zacks Investment Research” was posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this piece of content can be viewed at https://www.chaffeybreeze.com/2018/01/06/regulus-therapeutics-rgls-rating-increased-to-buy-at-zacks-investment-research.html.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Analyst Recommendations for Regulus Therapeutics (NASDAQ:RGLS)

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply